24 women (68.5%) were diagnosed with stage I breast cancer, 6 with stage II (17.14%) and 3 with stage III (8.5%) and the majority were on aromatase inhibitors (65.5%) versus 12 on tamoxifen (34.2 %). This evidence concerns the gene CYP19A1 and breast carcinoma.